| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Jae-Lyun Lee | |
| Yoon-Koo Kang | |||
| P2860 | cites work | Global cancer statistics, 2002 | Q27860562 |
| Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue | Q27863454 | ||
| Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 | ||
| Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine | Q28255790 | ||
| Hexamethylmelamine and Low or Moderate Dose Cisplatin With or Without Pyridoxine for Treatment of Advanced Ovarian Carcinoma: A Study of the Eastern Cooperative Oncology Group | Q28292277 | ||
| Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world | Q29614969 | ||
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data | Q31044850 | ||
| Acute coronary syndrome induced by oral capecitabine | Q33235644 | ||
| Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer | Q33341957 | ||
| Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. | Q33342773 | ||
| A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma | Q33343923 | ||
| Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer | Q33345470 | ||
| Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study | Q33366028 | ||
| Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer | Q33370007 | ||
| Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A Phase II trial | Q33377409 | ||
| Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer | Q33488159 | ||
| Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). | Q33490444 | ||
| Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine | Q33502454 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| Progress in colorectal cancer chemotherapy: how far have we come, how far to go? | Q34067396 | ||
| Capecitabine: preclinical pharmacology studies | Q34084259 | ||
| Clinical pharmacokinetics of capecitabine | Q34207262 | ||
| Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer | Q34366342 | ||
| Capecitabine as adjuvant treatment for stage III colon cancer | Q34429990 | ||
| Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen | Q34505635 | ||
| Cellular and molecular aspects of drugs of the future: oxaliplatin. | Q34530509 | ||
| Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 | ||
| Epidemiology of upper gastrointestinal malignancies | Q35857418 | ||
| Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma | Q36381830 | ||
| A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer | Q36614036 | ||
| Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer | Q36614109 | ||
| Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer | Q36614248 | ||
| Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer | Q36614394 | ||
| A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer | Q36614734 | ||
| Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer | Q36673543 | ||
| A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer | Q36694899 | ||
| Cellular pharmacology of fluorinated pyrimidines in vivo in man. | Q38651251 | ||
| Thalidomide use and digital gangrene | Q39775425 | ||
| Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer | Q40446766 | ||
| Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. | Q40449162 | ||
| Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy | Q40538283 | ||
| A molecular biological study of anti-tumor mechanisms of an anti-cancer agent Oxaliplatin against established human gastric cancer cell lines | Q40611137 | ||
| Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). | Q40613157 | ||
| Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial | Q42285544 | ||
| Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer | Q43519495 | ||
| Coronary spasm induced by capecitabine | Q43658220 | ||
| UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial | Q43723217 | ||
| Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models | Q43949117 | ||
| Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients | Q43949124 | ||
| A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Gastric Cancer | Q44405286 | ||
| A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting | Q44616079 | ||
| Capecitabine induces severe angina-like chest pain | Q44801262 | ||
| The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine | Q44935787 | ||
| A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. | Q45023409 | ||
| Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer | Q46415357 | ||
| The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). | Q46566900 | ||
| Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer | Q46592440 | ||
| A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer | Q46601885 | ||
| Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer | Q46610846 | ||
| Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma | Q46689601 | ||
| Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group | Q46960507 | ||
| Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | Q53604465 | ||
| Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. | Q53610419 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | capecitabine | Q420207 |
| P304 | page(s) | 179-198 | |
| P577 | publication date | 2008-04-01 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Capecitabine in the treatment of advanced gastric cancer | |
| P478 | volume | 4 |
| Q38391749 | Capecitabine plus paclitaxel induction treatment in gastric cancer patients with liver metastasis: a prospective, uncontrolled, open-label Phase II clinical study. |
| Q34603290 | Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. |
| Q37477979 | Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer |
| Q35331782 | Evidence based radiation therapy for locally advanced resectable and unresectable gastric cancer |
| Q35027279 | Preliminary estimation of the prevalence of chemotherapy-induced dysgeusia in Japanese patients with cancer |
| Q37781051 | Safety of capecitabine: a review |
Search more.